Schmidt M, Fasching P A, Beckmann M W, Kölbl H
Klinik für Geburtshilfe und Frauenkrankheiten, Universitätsmedizin Mainz, Mainz.
Frauenklinik, Universitätsklinikum Erlangen, Erlangen.
Geburtshilfe Frauenheilkd. 2012 Sep;72(9):819-832. doi: 10.1055/s-0032-1315340.
The therapy of choice for breast cancer patients requiring adjuvant chemo- or radiotherapy is increasingly guided by the principle of weighing the individual effectiveness of the therapy against the associated side effects. This has only been made possible by the discovery and validation of modern biomarkers. In the last decades and in the last few years some biomarkers have been integrated in clinical practice and a number have been included in modern study concepts. The importance of biomarkers lies not merely in their prognostic value indicating the future course of disease but also in their use to predict patient response to therapy. Due to the many subgroups, mathematical models and computer-assisted analysis are increasingly being used to assess the prognostic information obtained from established clinical and histopathological factors. In addition to describing some recent computer programmes this overview will focus on established molecular markers which have already been extensively validated in clinical practice and on new molecular markers identified by genome-wide studies.
对于需要辅助化疗或放疗的乳腺癌患者，治疗方案的选择越来越遵循权衡治疗的个体有效性与其相关副作用的原则。这只有通过现代生物标志物的发现和验证才得以实现。在过去几十年以及过去几年中，一些生物标志物已被纳入临床实践，还有一些被纳入现代研究概念。生物标志物的重要性不仅在于其指示疾病未来进程的预后价值，还在于其用于预测患者对治疗的反应。由于存在许多亚组，数学模型和计算机辅助分析越来越多地用于评估从既定临床和组织病理学因素中获得的预后信息。除了描述一些近期的计算机程序外，本综述将重点关注已在临床实践中得到广泛验证的既定分子标志物以及通过全基因组研究确定的新分子标志物。
